 Some new documents are out regarding the long-term effects of Moderna's RSV shot. The CDC says the shot dropped from 55% efficacy in the first 12 months to 36% in the second year for patients who displayed at least three lower respiratory symptoms. Pfizer's RSV shot declined from 86% the first year to 74% in the second. Moderna shares today were down more than 11%.